A pharmaceutically acceptable salt of aminoindazole compound

Abstract

The present invention relates to a racemate, enantiomer, disatereoisomer or a mixture thereof, or a tautomer or a pharmaceutically acceptable salt of a compound of formula (I): in which R3 is a (1-6C)alkyl, aryl, aryl(1-6C)alkyl, heteroaryl, heteroary1(1-6C)alkyl, aryl or heteroaryl fused to a (1-10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, COOR1, SO2R1, C(=NH)R1 or C(=NH)NR1 radical; R5 and R6 are, independently of one another, chosen from the following radicals: halogen, CN, NO2, NH2, OH, COOH, C(O)OR8, -O-C(O)R8, NR8R9, NHC(O)R8, C(O)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(O)R8, SO2R8, NHSO2R8, SO2NR8R9, -O-SO2R8, -S02-0 R8, trifluoromethyl, trifluoromethoxy, (1 6C)alkyl, (1-6C)alkoxy, aryl, aryl(1 6C)alkyl, heteroaryl, heteroary1(1-6C)alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl, adamantyl or polycycloalkyl.